Logo

Pfizer and BioNTech Delay FDA Request to Expand COVID-19 Vaccine in Children Under 5 Years of Age

Share this

Pfizer and BioNTech Delay FDA Request to Expand COVID-19 Vaccine in Children Under 5 Years of Age

Shots:

  • The US FDA postponed the Vaccines and Related Biological Products Advisory Committee meeting to discuss the request for authorization of Pfizer-BioNTech’s COVID-19 vaccine for children 6mos. through 4yrs. of age
  • The delay will provide the agency a time to evaluate the additional vaccine data and make a recommendation on the authorization of a two-dose series
  • The companies will wait for the three-dose data as Pfizer and BioNTech continue to believe it may provide a higher level of protection in this age group. The companies expected to have three-dose protection data available in early April 2022

 Ref: PR Newswire | Image: Pfizer

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions